Neuropilin-1 Regulates Vascular Endothelial Growth
Factor-Mediated Endothelial Permeability V ascular endothelial growth factor (VEGF) was first isolated and purified from tumor cells because of its ability to markedly increase vascular permeability to plasma proteins. 1 VEGF is expressed normally in most tissues, including lung, 2, 3 with abundant expression of VEGF in alveolar cells of normal rats. 3, 4 Published data support a significant role for VEGF in the development of acute lung injury and acute respiratory distress syndrome (ARDS) after various insults. [5] [6] [7] [8] [9] [10] In the adult lung, VEGF may promote vascular injury 6 -9,11 via effects on increased endothelial permeability. On the other hand, VEGF stimulates endothelial cell proliferation 12 and chemotaxis, 13 potential reparative responses to pulmonary vascular injury. Because cellular responses to VEGF may be either injurious or reparative, understanding how the endothelium transduces specific VEGF-mediated signals is critical.
Vascular endothelial cells express 2 tyrosine kinase receptors for VEGF, termed VEGF receptor 1 (VEGFR1) 14 and VEGF receptor 2 (VEGFR2). 15 Intermolecular cross-talk between VEGFR1 and VEGFR2 has been reported, 16 -18 and represents one possible pathway for differential regulation of VEGF signals. Endothelial cells also express neuropilin-1 (Npn-1), a class 3 semaphorin receptor, which binds VEGF 19 in an isoform-specific manner. 20 -23 The importance of Npn-1 in vasculogenesis was confirmed by recent murine studies demonstrating that constitutive or endothelial-specific Npn-1 deletion led to disrupted cardiac and vascular development, with embryonic lethality. 24, 25 Additionally, the phenotype of Npn-1 transgenic mice was similar to that reported for mice constitutively overexpressing VEGF, 26 with excess capillary formation, dilated blood vessels, extensive hemorrhage, and embryonic lethality, 27 suggesting a possible role for Npn-1 in enhanced vascular permeability as well as vasculogenesis and angiogenesis.
Npn-1 has a short intracellular domain with no predicted signaling functions. 28 In vitro, Npn-1 can complex with VEGFR1 and VEGFR2 23, 29, 30 and may potentiate VEGFR2 activation. 23, 30 Prior evidence supports a clear role for VEGFR2 in VEGF-mediated chemotaxis and proliferation, 13, 31, 32 but the cell surface receptors mediating VEGFinduced endothelial permeability have been less extensively evaluated. 33, 34 Although several studies support a role for VEGFR2 in VEGF-induced vascular barrier dysfunction, 33, 34 previous studies from our laboratory 35 and others 36 suggest that VEGFR2 may not be sufficient to elicit endothelial permeability responses to VEGF. Because upstream events that differentially activate VEGF receptors can modulate the physiologic response of endothelium to VEGF, 17, 18 we hypothesized that Npn-1 might be a required component of the pathway regulating VEGF-induced vascular permeability. To test this hypothesis, we determined the effects of Npn-1 overexpression and inhibition on VEGF-mediated endothelial cell permeability, and VEGFR2 activation, in vitro. To understand whether the effects of Npn-1 were specific to VEGF-induced vascular barrier dysfunction, we evaluated whether Npn-1 overexpression and inhibition comparably altered VEGF-mediated endothelial-cell chemotaxis. Finally, the effects of Npn-1 inhibition on VEGF-induced pulmonary vascular permeability were measured in vivo, by studying mice that overexpress VEGF in inducible, lung-specific fashion.
Materials and Methods

Reagents and Endothelial Cell Culture
See the online data supplement available at http://circres. ahajournals.org.
Endothelial Cell Transfection
Npn-1 was subcloned from pMT21 into pcDNAHygro, then porcine aortic endothelial cells (PAE) stably expressing VEGFR2 (PAE/ KDR) 32 were transfected with 0.2 to 0.4 g DNA using Lipofectamine (Invitrogen, Carlsbad, Calif), according to the manufacturer's instructions. Growth media containing 0.2 mg/mL Hygromycin (Calbiochem, San Diego, Calif), or 0.5 mg/mL G418 and Hygromycin, was used to select for clones expressing Npn-1 or both VEGFR2 and Npn-1 (PAE/KDR/Npn-1), respectively. Stably transfected cells were identified by Western blot analysis of cell lysates. Shown in Figure 1 , PAE did not express Npn-1 or VEGFR2 before transfection. PAE/KDR expressed VEGFR2, but not Npn-1, whereas PAE/Npn-1 expressed Npn-1, but not VEGFR2. PAE/KDR/ Npn-1 expressed both VEGFR2 and Npn-1. Similarly, human pulmonary artery endothelial cells (HPAE) expressed both VEGFR2 and Npn-1. No PAE-derived cell line expressed either VEGFR1 or Npn-2, whereas HPAE expressed VEGFR1, but not Npn-2 (data not shown).
Measurement of Transendothelial Electrical Resistance
Effects of rhVEGF on barrier function of stably transfected PAE, or HPAE, were assessed by measurement of transendothelial electrical resistance (TER) using electric cell-substrate impedance sensing (Applied Biophysics), as previously described 35 (see online data supplement).
Western Blot Analysis
VEGFR2, and p38 and ERK1/2 MAP kinase activation, were determined as previously described 9, 35 (see online data supplement).
Measurement of Endothelial Cell Chemotaxis
Assessment of endothelial cell chemotaxis was performed as previously described, 35 with minor modifications. Data represent the meanϮSE value from 3 separate experiments performed in duplicate within each experiment (see online data supplement).
Confocal Microscopy
After VEGF treatment, endothelial cell monolayers were processed for immunofluoresence microscopy as previously described. 35 Cover slips were mounted and analyzed using a Zeiss LSM510 confocal microscope with a Plan-Neofluor 40ϫ oil objective (NAϭ1.3). Z-stacks of 2-dimensional immunofluorescent images of VEGFR2 and actin were recorded simultaneously using the multitrack mode to prevent bleed-through. Images were processed, and 3-D images were reconstructed using LSM 510 software (version 3.2 SP2) and then stored for further management using Adobe Photoshop software.
Animal Protocols
The CC10-rtTA-VEGF mice used in this study were generated as previously described 37, 38 (see online data supplement). Npn-1 neutralizing antibodies or nonimmune rabbit IgG (50 g IP) were administered every 24 hours, then mice were euthanized under general anesthesia after 48 hours of exposure to doxycycline. The left lung was rapidly excised and weighed then placed in a desiccating oven (65°C) and weighed daily for 7 days until lung dry weight stabilized for calculation of wet/dry lung weight ratios. The right lung was snap-frozen in liquid nitrogen, then stored at Ϫ80°C until the tissue was homogenized for protein extraction and Western blot analysis. CC10-rtTA-VEGF mice receiving no doxycycline and wild-type littermates receiving 48 hours doxycycline served as additional controls.
Statistical Analysis
Statistical comparisons were made using analysis of variance (see online data supplement). When significant variance ratios were obtained, the least significant differences were calculated to allow comparison of individual group means. Differences were considered significant for probability values Յ0.05.
Results
Effects of Npn-1 Overexpression on Endothelial Cell Permeability
To determine the effects of Npn-1 on VEGF-mediated endothelial barrier dysfunction, TER of PAE/Npn, PAE/KDR, and PAE/KDR/Npn-1 was measured after administration of VEGF 165 . As shown in Figure 2A , TER of PAE/KDR/Npn-1 decreased in a dose-dependent manner after concentrations of VEGF 165 between 10 to 200 ng/mL. In contrast, VEGF 165 did not alter permeability of PAE/KDR ( Figure 2B ) or PAE/ Npn-1 ( Figure 2C ). Shown in Figure 2B and 2D, TER of PAE/KDR/Npn-1 decreased 14Ϯ6% within 36 minutes of 200 ng/mL VEGF 165 administration, as compared with a 4Ϯ3% increase in TER of PAE/KDR (PϽ0.0001). The decreased TER in PAE/KDR/Npn-1 was time-dependent and sustained, reaching a nadir of Ϫ49Ϯ8% 6 hours after administration of VEGF 165 . In contrast, the maximal decrease in TER in PAE/KDR 6 hours after the same concentration of VEGF 165 was Ϫ8Ϯ8% (PϽ0.0001). Shown in Figure 2C and 2E, the response of PAE/Npn-1 was comparable to that of PAE/KDR, with a ⌬TER of 3.3Ϯ2.8% and Ϫ6.5Ϯ4.2% after 36 and 360 minutes exposure to 200 ng/mL VEGF 165 .
The effects of permeability-enhancing concentrations of VEGF 165 on activation of VEGFR2 also differed. Shown in Figure 3 , treatment of both PAE/KDR and PAE/KDR/ Npn-1 with 200 ng/mL VEGF 165 resulted in rapid phosphorylation of VEGFR2, but the amount of phosphorylated VEGFR2 (p-VEGFR2) was greater, and activation was more rapid, in PAE/KDR/Npn-1 as compared with PAE/ KDR. This difference was paralleled by increased and sustained activation of the downstream signaling molecules, ERK1/2 and p38 mitogen activated protein kinase (MAPK), in PAE/KDR/Npn-1, as compared with PAE/ KDR (middle and bottom panels of Figure 3 ). Shown in Figure 3 , differences in VEGFR2 and MAPK activation were not attributable to increased amounts of VEGFR2 or MAPK protein as a consequence of Npn-1 expression.
To determine whether Npn-1 altered the cellular distribution of activated VEGFR2, confocal microscopy of confluent endothelial cell monolayers was performed after administration of permeability-enhancing concentrations of VEGF 165 . Cells were double immunostained for p-VEGFR2 and cellular actin. Shown in Figure 4A and 4B are representative results from 3 separate experiments. In both figures, sagittal sections reconstructed from Z-stack images are shown in the top panels. The remaining panels represent 2-D scans at varying levels within the monolayer (apical, medial, and basal). The panels on the left side of each figure represent control cells not exposed to rhVEGF, whereas the panels on the right side of each figure represent cells fixed 5 minutes after administration of VEGF 165 (200 ng/mL). In control untreated PAE/KDR ( Figure 4A ), little p-VEGFR2 expression was seen. VEGF treatment resulted in increased actin stress fiber formation, with p-VEGFR2 appearing at the tips of actin stress fibers. In contrast, as shown in Figure  4B , p-VEGFR2 expression was increased under control conditions in PAE/KDR/Npn-1, and there appeared to be more depolymerized cellular actin present. After VEGF 165 administration, there was a pronounced increase in the expression of p-VEGFR2 in PAE/KDR/Npn-1. In addition to increased expression of p-VEGFR2 at tips of actin stress fibers, polarity-dependent differential expression of p-VEGFR2 was seen, such that activated VEGFR2 was prominently localized to the apical cell membrane ( Figure  4B , top).
To compare the effect of Npn-1 expression on VEGFinduced endothelial cell permeability with previous reports in the literature regarding how Npn-1 alters VEGF-mediated endothelial cell migration, the effects of VEGF 165 on chemotaxis of PAE/KDR and PAE/KDR/Npn-1 was compared. As shown in Figure 5 , basal chemotaxis did not differ between these 2 cell types. Although Npn-1 expression enhanced chemotaxis in response to VEGF, as has been previously reported, 19 it was not required, as both PAE/KDR and PAE/KDR/Npn-1 migrated efficiently in response to VEGF.
Effects of Npn-1 Inhibition on VEGF-Mediated Lung Endothelial Cell Permeability In Vitro
To determine whether Npn-1 inhibition attenuated VEGFmediated pulmonary endothelial cell permeability, 200 ng/mL VEGF 165 was administered to HPAE after pretreatment with Npn-1 or VEGFR2 neutralizing antibodies, alone or in combination, or nonimmune IgG. Pretreatment with Npn-1 neutralizing antibodies resulted in attenuation of endothelial barrier dysfunction at all time points after VEGF 165 treatment ( Figure 6A , top). In contrast, VEGFR2-neutralizing antibodies did not prevent decreased TER after VEGF 165 , although VEGFR2-neutralization may have resulted in a less sustained effect of VEGF 165 on endothelial barrier function (Pϭ0.025; Figure 6A , middle). The combination of both Npn-1 and VEGFR2 neutralizing antibodies appeared the most effective strategy for attenuating VEGF-induced HPAE permeability ( Figure 6A , bottom). In contrast with permeability, VEGFR2-neutralization completely attenuated VEGFmediated chemotaxis of HPAE (PϽ0.0001), whereas Npn-1 inhibition only partially blocked this response ( Figure 6B ).
To confirm a role for Npn-1 in mediated vascular barrier dysfunction in human lung endothelial cells, we compared the effects of 2 VEGF isoforms, VEGF 121 and VEGF 165 , on TER of HPAE. VEGF 165 , used for all of the other experiments in this study, ligates all VEGF receptors expressed on these cells, including VEGFR1, VEGFR2, and Npn-1. In contrast, VEGF 121 binds VEGFR1 and VEGFR2, but not Npn-1. Consistent with the effects of Npn-1 neutralization on VEGFinduced barrier dysfunction, VEGF 121 had no effect on TER of HPAE, when compared with comparable concentrations of VEGF 165 (Figure 7) .
Effects of Npn-1 Inhibition on VEGF-Mediated Vascular Permeability In Vivo
To determine whether Npn-1 modulated VEGF response in vivo, the effects of Npn-1 neutralizing antibodies on pulmonary vascular permeability and VEGFR2 activation were determined in mice inducibly overexpressing human VEGF 165 in lung-specific fashion. 37, 38 Pulmonary VEGF expression was induced by administration of doxycycline in drinking water for 48 hours, immediately after injection of rabbit anti-rat Npn-1 neutralizing antibodies (50 g IP Q24 hoursϫ2 doses), or comparable amounts of nonimmune rabbit IgG. Pulmonary vascular permeability, estimated by measurement of lung wet/dry weight ratio, increased significantly after induction of VEGF in IgG-treated animals ( Figure 8A ). In contrast, Npn-1 neutralization significantly attenuated VEGF-mediated vascular leak (Pϭ0.04). Shown in Figure 8B , Western blot analysis of whole-lung homogenates demonstrated that Npn-1 neutralizing antibodies significantly attenuated VEGFR2 phosphorylation, and p38 and ERK1/2 MAPK activation, after the induction of VEGF.
Discussion
Mounting experimental evidence supports a significant role for VEGF in the development of acute lung injury. Kaner et al demonstrated that overexpression of VEGF in murine lung, using adenoviral transfection, was associated with profound pulmonary edema. 7 These data are supported by recent studies in transgenic mice, where lungspecific overexpression of VEGF 165 caused hemorrhage 11 and edema 38 formation. Additionally, increased pulmonary VEGF expression was shown in response to inhaled lipopolysaccharide (LPS), in association with increased BAL protein concentration and neutrophil influx. 8 These reports are consistent with our published studies, which demonstrated that increased pulmonary vascular permeability induced by ventilated pulmonary ischemia in both ferret and mouse lungs was linked with significant upregulation of VEGF. 6, 9 Emerging clinical studies have confirmed these experimental data. Recent reports demonstrated increased expression of VEGF in preserved humanlung allografts, in association with increased wet/dry lung weight ratios, 5, 39 and plasma VEGF was shown to increase during the first 48 hours after presentation in 40 ARDS patients. 10 Npn-1 binds VEGF, and in vitro studies suggest that this receptor can enhance VEGF signaling through VEGFR2, 30 as well as perhaps through other pathways. 40 Our data suggest that Npn-1 is required for VEGF-mediated vascular barrier dysfunction, as PAE expressing only VEGFR2 exhibited no permeability change in response to VEGF 165 . In contrast, coexpression of Npn-1 with VEGFR2 completely restored VEGF-induced endothelial leak in a dose-dependent manner. Stable transfection of PAE with Npn-1 alone was insufficient to cause VEGF-mediated endothelial barrier dysfunction. Consistent with these findings, inhibition of Npn-1 attenuated VEGF 165 -mediated barrier dysfunction of HPAE, which express both VEGFR2 and Npn-1, as well as VEGFR1. Interestingly, although a few prior studies in other model systems suggested that VEGF 121 could increase vascular permeability, [51] [52] [53] 41, 42 To determine whether the effects of Npn-1 were specific for VEGF-induced endothelial permeability, we evaluated the consequences of Npn-1 expression and inhibition on VEGFmediated endothelial cell chemotaxis. In contrast to barrier dysfunction, stable expression of VEGFR2 alone was sufficient to allow chemotaxis in response to VEGF 165 . Consistent with this, inhibition of VEGFR2 completely prevented the chemotaxis of HPAE to VEGF. These data support several prior studies demonstrating a critical role for VEGFR2 in VEGF-induced endothelial chemotaxis and proliferation. 13, 18, 31 As has been previously reported, stable coexpression of Npn-1 and VEGFR2 enhanced VEGF-mediated endothelial chemotaxis, 19, 43 and Npn-1 inhibition partially attenuated human pulmonary artery VEGF-mediated endothelial cell migration. These data suggest that although Npn-1 may modulate endothelial chemotaxis to VEGF, it is not required to elicit this response. In contrast, Npn-1 appears to be critical for VEGF-mediated endothelial permeability.
Our data also demonstrate that Npn-1 coexpression resulted in increased activation of ERK1/2 and p38 MAPK in response to permeability-enhancing concentrations of VEGF. We, and others, previously reported that inhibition of either ERK1/2 35, 44 or p38 35 MAPK attenuated VEGF-induced endothelial cell barrier dysfunction in vitro. The finding that Npn-1 expression enhanced activation of p38 and ERK 1/2 MAPK therefore supports the hypothesis that Npn-1 is an important component of the pathway mediating endothelial permeability in response to VEGF. However, the current study was designed to evaluate whether Npn-1/VEGFR2 complexes determine specificity of the cellular response to VEGF, and did not investigate the specific intracellular signaling events mediating endothelial barrier dysfunction.
Although the VEGF receptors and signaling pathways implicated in VEGF-induced endothelial cell mitogenicity and migration have been extensively studied, 13,31,32 the mechanisms of VEGF-mediated endothelial permeability enhancement have been less comprehensively evaluated. 33, 34 The literature is inconsistent regarding the specific VEGF receptors transducing VEGF-mediated vascular leak, 42, 45, 46 and the majority of in vitro studies of endothelial permeability have used varying concentrations of the 165 isoform of VEGF. 33, 44, [47] [48] [49] In addition, permeability assays vary between studies, and may therefore reflect differing aspects of vascular barrier dysfunction. 50 No currently available in vitro permeability assay can adequately reproduce the in vivo situation. On the other hand, in vivo permeability assays may be influenced by factors other than permeability. For example, the Miles assay commonly used to assess dermal vascular permeability measures the rate of tracer movement into tissue, and may depend on blood flow, capillary pressure, and vascular surface area, as well as permeability. Similarly, lung wet/dry weight, the assay reported in this study, may increase either because of increased lung water, vascular surface area, or both. Because of these limitations, results of different assays of permeability may yield discrepant results.
Although methods for estimating permeability in vitro and in vivo are not directly comparable, in the current study results of in vivo experiments were consistent with in vitro experiments. Administration of Npn-1 neutralizing antibodies prevented the development of pulmonary edema after the induction of VEGF expression in transgenic mice expressing human VEGF 165 in externally regulable, lung-specific fashion. This protection from VEGF-induced increased lung water was linked with attenuation of VEGFR2, ERK1/2, and p38 MAPK activation, measured by Western blot analysis in whole lung homogenates. Although the increased wet/dry A, Lung wet/dry weight ratio increased in CC10-rtTA-VEGF mice after induction of pulmonary VEGF 165 expression with doxycycline. This increase in lung water was attenuated by pretreatment with ␣-Npn-1 (50 g IP; nϭ4 to 6 per group). B, Representative Western blot analysis of whole-lung homogenates from the same mice demonstrated that ␣-Npn-1 decreased activation of VEGFR2, and p38, and ERK1/2 MAPK after pulmonary VEGF induction. Expression of total lung Npn-1 protein did not differ between groups (nϭ4 per group). lung weight ratio elicited by VEGF induction was small, it was statistically significant and consistent with prior reports of VEGF-induced vascular leak in these animals. 38 It should be noted that lung wet/dry weight ratio may increase secondary to increased vascular permeability, increased vascular surface area, or both. To minimize any contribution of the latter to this measurement, we chose to evaluate the effects of Npn-1 inhibition at an early time point (48 hours) of VEGF induction. This choice was based on published data that pulmonary VEGF expression in CC10-rtTA-VEGF transgenic mice was not maximal until 48 hours of doxycycline induction, whereas longer periods (3 to 5 days) of VEGF induction stimulated angiogenesis, which might increase vascular surface area and complicate estimation of permeability. 37 To evaluate the involvement of VEGFR2 in Npn-1-mediated endothelial barrier dysfunction, we compared VEGFR2 activation after permeability-enhancing concentrations of VEGF in cells expressing VEGFR2 alone and cells expressing both VEGFR2 and Npn-1. Coexpression of Npn-1 and VEGFR2 potentiated phosphorylation of VEGFR2, measured both by Western blot and immunocytochemistry. Furthermore, confocal microscopy demonstrated that Npn-1 altered the cellular distribution of activated VEGFR2, such that VEGF induced polarity-dependent localization of p-VEGFR2 to the apical cell membrane. Additionally, in vivo experiments suggested that Npn-1 inhibition attenuated VEGFR2 activation. These data extend published studies demonstrating that Npn-1 can complex with VEGFR2 in vitro 23, 29, 30 and may potentiate VEGFR2 activation. 23, 30 On the other hand, VEGFR2 expression alone was insufficient to increase permeability of PAE in response to VEGF, and VEGFR2 inhibition did not attenuate VEGF-mediated barrier dysfunction of HPAE. These data suggest that enhanced endothelial permeability in response to VEGF may involve signaling through pathways 40 -42 in addition to those activated by VEGFR2. Because human lung endothelial cells express VEGFR1 in addition to VEGFR2 and Npn-1, future studies will evaluate whether VEGFR1 modulates the effects of Npn-1 on VEGF-induced vascular leak. A possible role for VEGFR1 in vascular permeability was suggested by a recent report that snake venom vascular endothelial growth factor (TfsvVEGF) preferentially phosphorylates VEGFR1 over VEGFR2 and enhances permeability assessed by the Miles assay. 46 This study did not report whether TfsvVEGF bound Npn-1.
Taken together, these data demonstrate an important role for Npn-1 in VEGF-induced vascular permeability and support the hypothesis that increased Npn-1 expression or activation represents one pathway by which diverse physiologic responses of vascular endothelium to VEGF may be differentially mediated. Increased lung VEGF expression can cause pulmonary edema, the primary clinical manifestation of ARDS. Our results suggest that strategies targeting Npn-1 may lead to the development of novel therapeutic approaches to attenuate the injurious consequences of VEGF in this complex clinical disorder. Chemotaxis filters were soaked in 0.2% gelatin for 1 hr at room temperature and airdried 30' at sterile conditions. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise specified.
Endothelial cell culture.
Porcine aortic endothelial cell lines were maintained in Ham's F-12
(Invitrogen), supplemented with 10% fetal bovine serum (FBS; Irvine Scientific, Santa Ana, CA), 1% antibiotic solution (penicillin, 10,000 units/ml; streptomycin, 10 µg/ml; amphotericin B 250 µg/ml; Biosource International, Camarillo, CA), 2mM glutamine (Mediatech, Inc; Herndon, VA), and 0.5 mg/ml G418 (Invitrogen).
Human pulmonary artery endothelial cells were obtained frozen at 4th
passage from Cambrex Corporation (East Rutherford, NJ), and utilized at passage 5-9. Cells were cultured in EBM TM supplemented with the EGM-2 Bullet Kit Western blot analysis.
VEGFR2, and p38 and ERK1/2 MAP kinase activation, were determined as previously described 2,3 by immunoblotting endothelial cell or whole lung lysates with specific phospho-VEGFR2, phospho-ERK or phospho-p38 antibodies, which indicate the enhanced catalytic activity of the enzymes. Expression of activated protein was normalized to expression of total VEGFR2, ERK1/2 or p38 MAPK, respectively, measured on the same membranes.
Immunofluoresence microscopy.
After probing with phospho-VEGFR2 antibodies (4 µg/ml) for 1 hour, cells were washed, then incubated with Alexa-fluorophore 488 -labelled goat anti-rabbit IgG
(1:300 dilution) and 1 U/ml Texas Red-phalloidin.
CC10-rtTA-VEGF mice. Chemotaxis filters were soaked in 0.2% gelatin for 1 hr at room temperature and airdried 30' at sterile conditions. All other reagents were purchased from Sigma-Aldrich Western blot analysis.
CC10-rtTA-VEGF mice.
CC10-rtTA-VEGF mice over-express human VEGF 165 in lung epithelium in an externally regulatable manner 4 . Mice were housed in barrier conditions with veterinary supervision, and animal protocols were approved by the Animal Care and Use Committee at the Johns Hopkins University School of Medicine. Male CC10-
